Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss Rockets AG incubator, has announced highly encouraging results from its…
TCGX Closes Oversubscribed $1.3 Billion Fund III, Strengthening Its Position in Global Biopharma Investment TCG Crossover (“TCGX”), a leading global investment firm focused on the biotechnology and life sciences sector, announced the successful close of its third fund—TCGX Fund III—with…
Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL 30 mg tablets throughout…
Kardigan Accelerates Development of Transformative Cardiovascular Medicines Across Three Critical Disease Areas Kardigan, a pioneering heart health company dedicated to modernizing cardiovascular drug development, today unveiled the three late-stage clinical programs that anchor its rapidly advancing pipeline. These programs represent…
Embracing Communities of Innovation: Massachusetts Our strategy to transform patients’ lives has always centered on building state-of-the-art research centers within communities that spark innovation. Massachusetts stands as a global hub for life sciences, home to some of the brightest minds…
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations…
Employee-led initiative supports global partnerships to build stronger, climate-resilient health systems Takeda (TSE:4502/NYSE:TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to building…
Silent global health crisis threatens lives, driving heart disease, stroke, and kidney failure worldwide The World Health Organization (WHO) today released its second Global hypertension report, showing that 1.4 billion people lived with hypertension in 2024, yet just over one in…
Potential First Approved Treatment in the EU Targeting NF1-Associated Plexiform Neurofibromas koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with…
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The Committee…
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced that the first patient has…
European Commission Grants Approval for Henlius and Organon’s Denosumab Biosimilars BILDYOS® and BILPREVDA® Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a significant regulatory milestone with the news that the European Commission (EC) has granted marketing authorization for…